Drugs / Autologous BM MSC
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03626090 | Aug 2018 → Oct 2021 | cirrhosis of liver | Stem Med Pte. Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05066334 | Mar 2021 → Oct 2025 overdue | chronic pain syndrome, intervertebral disk degenerative disorder | Fondazione Policlinico Universitario Campus Bio-Medico | Recruiting | No outcome recorded |
| Phase 2 | NCT04759105 | Nov 2019 → Nov 2023 | chronic pain syndrome, intervertebral disk degenerative disorder | Fondazione Policlinico Universitario Campus Bio-Medico | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05080465 | Dec 2018 → Oct 2024 | cirrhosis of liver | Ukraine Association of Biobank | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous BM MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05080465 ↗ |
| Modality | Cell therapy | “Cell Therapy” NCT03626090 ↗ |
| Route | Intravenous | “will be infused via peripheral venous access.” NCT03626090 ↗ |